NT-ProBNP Change Prognostic in Acute HF

March 04, 2011

March 4, 2011 (Baltimore, Maryland) — A <50% drop in natriuretic peptides during hospitalization for acute heart failure points to greater risk of death or rehospitalization within a year, suggests a prospective cohort study [1].

The prognostic power of such a change in N-terminal pro-brain-type natriuretic peptide (NT-proBNP) levels was independent of a range of more standard risk indicators, such as admission creatinine, LVEF, and comorbidities, according to the authors, led by Dr Henry J Michtalik (Johns Hopkins University School of Medicine, Baltimore, MD).

"This suggests that NT-proBNP could be a summary marker for many different variables, including HF severity, ischemia, hypertension with left ventricular hypertrophy, atrial fibrillation, and valvular disease," the group writes in a report published online February 4, 2011 in the American Journal of Cardiology. "The use of a single objective biomarker to account for multiple mechanisms of disease could benefit the care of a typical patient with HF who has many different comorbidities and risk factors."

The findings are consistent with a post hoc analysis of the SURVIVE trial, previously reported by heartwire , in which a natriuretic peptide drop of >30% independently predicted a nearly 50% decline in six-month mortality.

In the current study, 217 patients admitted with acute heart failure included 120 whose NT-proBNP levels changed by <50% during the hospitalization and 97 with changes of at least 50%; the cutoffs were prospective defined. Discharge for each patient was decided by a clinician who was blinded to discharge NT-proBNP levels.

The rate of readmission or death reached 3.2 and 2.2 per 1000 person-days, respectively. The hazard ratio for that end point at one year for those with a <50% change in the biomarker was 1.54 (95% CI 1.05–2.27, p=0.03), with adjustment for age, sex, race, admission creatinine and NT-proBNP levels, comorbidities (including hypertension, diabetes, CAD, atrial arrhythmias, chronic obstructive pulmonary disease, and peripheral vascular disease), and duration of index hospitalization.

A next step, according to the authors, might be a randomized trial of whether treatments aimed at pushing natriuretic peptide levels down by at least 50% at hospitalization improves postdischarge outcomes.

According to the paper, "the study was supported by an investigator-initiated grant . . .  from Siemens Healthcare Diagnostics."


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: